Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MA-0204 is a highly selective and orally available peroxisome proliferator-activated receptor δ (PPARδ) modulator (EC50s: 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively). It is a potential treatment for Duchene Muscular Dystrophy (DMD).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 147.00 | |
5 mg | In stock | $ 313.00 | |
10 mg | In stock | $ 528.00 | |
25 mg | In stock | $ 859.00 | |
50 mg | In stock | $ 1,190.00 | |
100 mg | In stock | $ 1,580.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 329.00 |
Description | MA-0204 is a highly selective and orally available peroxisome proliferator-activated receptor δ (PPARδ) modulator (EC50s: 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively). It is a potential treatment for Duchene Muscular Dystrophy (DMD). |
Targets&IC50 | PPARδ:0.4 nM (EC50)(in human), PPARδ:10 nM (EC50)(in rat), PPARδ:7.9 nM (EC50)(in mouse) |
In vitro | MA-0204 is >10,000-fold selective for activation of PPARδ over PPARα and PPARγ receptors. MA-0204 (1.2-12 nM) improves fatty acid oxidation in DMD patient muscle myoblasts mice. MA-0204 shows high protein binding to mouse plasma, good permeability, and low potential for efflux. C. |
In vivo | In the muscle, PPARδ (30, 100 mg/kg) enhances target gene transcription. |
Molecular Weight | 476.49 |
Formula | C25H27F3N2O4 |
CAS No. | 2095128-17-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 40 mg/mL (83.95 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MA-0204 2095128-17-7 DNA Damage/DNA Repair Metabolism PPAR MA 0204 inhibit Peroxisome proliferator-activated receptors MA0204 Inhibitor inhibitor